Millennium Management’s TG Therapeutics TGTX Stock Holding History

Millennium Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-7,200	Closed	-$284K	–	6324
2025 Q1	$284K	Buy	+7,200	New	+$242K	﹤0.01%	5128
2024 Q2	–	Sell	-60,000	Closed	-$913K	–	6534
2024 Q1	$913K	Sell	60,000 -49,500	-45%	-$789K	﹤0.01%	4369
2023 Q4	$1.87M	Buy	+109,500	New	+$1.27M	﹤0.01%	3670
2023 Q1	–	Sell	-734,200	Closed	-$8.69M	–	6858
2022 Q4	$8.69M	Buy	+734,200	New	+$5.33M	﹤0.01%	2287
2022 Q3	–	Sell	-444,500	Closed	-$1.89M	–	7493
2022 Q2	$1.89M	Buy	444,500 +344,500	+345%	+$2.15M	﹤0.01%	3764
2022 Q1	$951K	Buy	+100,000	New	+$1.16M	﹤0.01%	4585
2020 Q4	–	Sell	-85,000	Closed	-$2.27M	–	5582
2020 Q3	$2.27M	Buy	+85,000	New	+$1.96M	﹤0.01%	2497
2020 Q1	–	Sell	-123,000	Closed	-$1.36M	–	4471
2019 Q4	$1.36M	Buy	+123,000	New	+$935K	﹤0.01%	2842
2019 Q2	–	Sell	-807,100	Closed	-$6.49M	–	4451
2019 Q1	$6.49M	Buy	+807,100	New	+$4.36M	0.01%	1573

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Millennium Management's TGTX Position: Q2 2026 in Review

Millennium Management increased its TG Therapeutics (TGTX) stake by 122% in Q2 2026, buying an estimated $6.14M and bringing the position to 272,511 shares worth $15M. The position accounts for 0.01% of the portfolio, ranked #1892.

Millennium Management first reported a position in TGTX in Q3 2013 and has held it in 44 quarters since. The position peaked at $73.3M in Q4 2022. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Millennium Management held 272,511 shares of TG Therapeutics worth $15M as of Q2 2026.
Millennium Management bought 149,924 TG Therapeutics shares in Q2 2026, an estimated $6.14M.
TG Therapeutics made up 0.01% of Millennium Management's portfolio in Q2 2026, its #1892 holding.
Millennium Management first reported a position in TG Therapeutics in Q3 2013 and has held it in 44 quarters since.
Millennium Management's TG Therapeutics position peaked at $73.3M in Q4 2022.
429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.